A Study in Healthy People to Test Whether Iclepertin Has an Effect on Cardiac Safety
Status:
Active, not recruiting
Trial end date:
2024-05-28
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the effects of iclepertin in the range of therapeutic to
supra-therapeutic exposures on the (QT/QTc): Electrocardiogram (ECG) time interval from the
start of the QRS complex (ECG time interval) to the end of the T wave / QT interval corrected
for heart rate, e.g. using the method of Fridericia or Bazett interval and other ECG
parameters.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination